Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and cyclofenil

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with cyclofenil in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Studies
(cyclofenil)
Trials
(cyclofenil)
Recent Studies (post-2010) (cyclofenil)
9,1561875522002219

Protein Interaction Comparison

ProteinTaxonomy1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50)cyclofenil (IC50)
Estrogen receptorHomo sapiens (human)0.027

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gao, L; He, M; Ni, X; Sun, Y; Tang, G; Wang, L; Xu, B; Yu, Y1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and cyclofenil

ArticleYear
Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers.
    British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5

    Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Androgen Receptor Antagonists; Androgens; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclofenil; Dihydrotestosterone; Disease Progression; Estradiol; Hormone Antagonists; Humans; Imidazoles; Indoles; Male; Mifepristone; Platelet Activating Factor; Prostatic Neoplasms; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Wnt Proteins

2013